ST Wanbang: Announcement on the Subsidiary Obtaining the Notification of Granting Invention Patent Rights
Securities code: 002082 Securities abbreviation: ST Wanbang Announcement number: 2026-039
Wanbangde Pharmaceutical Holding Group Co., Ltd.
Announcement on the Subsidiary Obtaining the Notification of the Grant of Invention Patent Rights
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Wanbangde Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of Wanbangde Pharmaceutical Holding Group Co., Ltd. (hereinafter referred to as the "Company"), recently received the "Notice of Grant of Invention Patent Rights" from the State Intellectual Property Office. The details are as follows:
Title of invention: A disulfide cyclic peptide compound and its preparation method and application
Patent type invention patent
Patent number ZL202510986664.8
Patentee Wanbangde Pharmaceutical Group Co., Ltd.
This patent relates to a cyclic peptide compound with a specific disulfide bond structure, as well as its preparation method and wide range of clinical applications. As a highly selective ligand for melanocortin receptors, it can provide new candidate drug molecules for the treatment of acute or chronic inflammatory diseases, autoimmune diseases, transplant rejection, metabolic diseases accompanied by weight gain, metabolic diseases accompanied by weight loss, diabetes, diabetic complications, cancer, cancerous hyperplasia, reproductive system diseases, peripheral or central nervous system diseases, cardiovascular diseases or respiratory diseases. At the same time, the compound's novel structure has good targeting, stability, and biological activity. The research and development of innovative drugs for Alzheimer's disease, Parkinson's disease, myasthenia gravis, obesity and overweight, pemphigus and other diseases is of great significance.
The above-mentioned invention patents were obtained through the company's independent research and development and are the result of the company's continuous innovation. They are conducive to protecting the intellectual property rights of new drug research and development, promoting the company's self-research capabilities and scientific innovation capabilities, accelerating the research and development of new drugs, and improving the company's core competitiveness.
The company will handle the registration procedures strictly in accordance with the contents of the registration notice. After completing the registration procedures on time, the State Intellectual Property Office will make a decision to grant the patent right, issue an invention patent certificate, and register and announce it.
Announcement is hereby made.
Board of Directors of Wanbangde Pharmaceutical Holding Group Co., Ltd.
May 19, 2026